Avid Bioservices (NASDAQ: CDMO) reported Q2 EPS of ($0.27), $0.17 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $33.5 million versus the consensus estimate of $33.8 million.

For earnings history and earnings-related data on Avid Bioservices (CDMO) click here.